Jaguar Health, Inc.

For the period ended Mar 31, 2026. Filed May 20, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 20, 2026

JAGX$0.44+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Changes in Stockholders’ Deficit

IN STOCKHOLDERS’ DEFICIT

Series LPerpetual preferred stock · Series MPerpetual preferred stock · Series NPerpetual preferred stock · Common Stock - voting · Common Stock - non-voting · Additional paid-in · Noncontrolling · Accumulated · Accumulatedothercomprehensive · TotalStockholders'
(In thousands, except share data)	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	capital	interest	deficit	loss	equity (deficit)
Balances as of January 1, 2026	121	$2,485	144	$—	10	$—	199,330	$1	1	$—	$380,974	$(1,399)	$(399,916)	$(833)	$(18,688)
Common shares issued to Streeterville in exchange for pre-funded warrants	—	—	—	—	—	—	126,143	—	—	—	—	—	—	—	—
Common shares issued to Iliad in exchange for pre-funded warrants	—	—	—	—	—	—	45,843	—	—	—	—	—	—	—	—
Common shares issued to investors in exchange for Series N Preferred Stock	—	—	—	—	(10)	—	595	—	—	—	—	—	—	—	—
Common shares issued to investors in exchange for restricted stock units (RSUs)	—	—	—	—	—	—	69	—	—	—	—	—	—	—	—
Warrants issued to Iliad in exchange for Series L Preferred Stock	(22)	—	—	—	—	—	—	—	—	—	479	—	—	—	479
Warrants issued to Streeterville in exchange for Series L Preferred Stock	(99)	(2,485)	—	—	—	—	—	—	—	—	4,647	—	—	—	2,162
Preferred stock issued to Iliad on preferred returns of Series M Preferred Stock	—	—	9	—	—	—	—	—	—	—	—	—	—	—	—
Preferred stock issued to Streeterville on preferred returns of Series M Preferred Stock	—	—	4	—	—	—	—	—	—	—	—	—	—	—	—
Warrants issued to Iliad in exchange for Series M Preferred Stock	—	—	(88)	—	—	—	—	—	—	—	1,910	—	—	—	1,910
Warrants issued to Streeterville in exchange for Series M Preferred Stock	—	—	(69)	—	—	—	—	—	—	—	1,511	—	—	—	1,511
Warrants issued to investors in exchange for notes payable and accrued interest	—	—	—	—	—	—	—	—	—	—	179	—	—	—	179
Warrants issued to Iliad in exchange for Royalty Interest	—	—	—	—	—	—	—	—	—	—	2,222	—	—	—	2,222
Warrants issued to Streeterville in exchange for Royalty Interest	—	—	—	—	—	—	—	—	—	—	1,590	—	—	—	1,590
Stock dividends issued as Series O Convertible Preferred Stock	—	—	—	—	—	—	—	—	—	—	(9,470)	—	—	—	(9,470)
Deemed dividend to Iliad related to conversion of Series L Preferred Stock	—	—	—	—	—	—	—	—	—	—	(479)	—	—	—	(479)
Deemed dividend to Streeterville related to conversion of Series L Preferred Stock	—	—	—	—	—	—	—	—	—	—	(2,163)	—	—	—	(2,163)
Deemed dividend to Iliad related to conversion of Series M Preferred Stock	—	—	—	—	—	—	—	—	—	—	(1,910)	—	—	—	(1,910)
Deemed dividend to Streeterville related to conversion of Series M Preferred Stock	—	—	—	—	—	—	—	—	—	—	(1,511)	—	—	—	(1,511)
Stock issuance costs	—	—	—	—	—	—	—	—	—	—	(4)	—	—	—	(4)
Stock-based compensation	—	—	—	—	—	—	—		—	—	155	—	—	—	155
Net income (loss)	—	—	—	—	—	—	—	—	—	—	—	(126)	8,849	—	8,723
Translation loss	—	—	—	—	—	—	—	—	—	—	—	(49)	—	(409)	(458)
Balances as of March 31, 2026	—	$—	—	$—	—	$—	371,980	$1	1	$—	$378,130	$(1,574)	$(391,067)	$(1,242)	$(15,752)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES

IN STOCKHOLDERS’ DEFICIT

Series LPerpetual preferred stock · Series MPerpetual preferred stock · Series NPerpetual preferred stock · Common Stock - voting · Common Stock - non-voting · Additional paid-in · Noncontrolling · Accumulated · Accumulatedothercomprehensive · TotalStockholders'
(In thousands, except share data)	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	capital	interest	deficit	loss	equity (deficit)
Balances as of January 1, 2025	—	$—	—	$—	—	$—	15,098	$—	1	$—	$354,234	$(791)	$(346,482)	$(467)	$6,494
Common shares issued in At The Market offering, net of issuance and offering cost of $17	—	—	—	—	—	—	2,286	—	—	—	1,756	—	—	—	1,756
Common shares issued to Streeterville in exchange of notes payable and accrued interest	—	—	—	—	—	—	1,474	—	—	—	315	—	—	—	315
Common shares issued to Irving in exchange of notes payable and accrued interest	—	—	—	—	—	—	400	—	—	—	1,210	—	—	—	1,210
Warrants issued	—	—	—	—	—	—	—	—	—	—	1,795	—	—	—	1,795
Issuance costs attributable to warrants	—	—	—	—	—	—	—	—	—	—	(183)	—	—	—	(183)
Stock-based compensation	—	—	—	—	—	—	—		—	—	301	—	—	—	301
Net loss	—	—	—	—	—	—	—	—	—	—	—	(132)	(10,464)	—	(10,596)
Translation loss	—	—	—	—	—	—	—	—	—	—	—	(29)	—	(233)	(262)
Balances as of March 31, 2025	—	$—	—	$—	—	$—	19,258	$—	1	$—	$359,428	$(952)	$(356,946)	$(700)	$830

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.